How ready are european payers for ema adaptive pathways?

Are payers ready to reward quality and outcomes?

Are we ready for computerized adaptive testing?

369 Gibbons and colleagues’ article (1) in this issue highlights an emerging methodology of considerable value to psychiatric services. Computerized adaptive testing (CAT) has multiple advantages over standard paper-and-pencil assessment tools (2). CAT uses existing data to streamline and individualize the measurement process. By selecting items of particular relevance to an individual responde...

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation

Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. However, once medicines are approved through MAPPs, they will be evaluated for funding by payers through diff...

How to know when physicians are ready for genomic medicine.

Despite perceptions to the contrary, physicians are as prepared for genomic medicine as they are for other medical innovations; educational initiatives and support from genetics specialists can enhance clinical practice.

Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition of unmet need. Conditional approval pathways already exist for new medicines for seriously debil...